Evidence map›Paper›PMID 35587714›Full record

ArticleESC heart failure2022

Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment.

Manting Choy, Weihao Liang, Jiangui He, Michael Fu, Yugang Dong, Xin He, Chen Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESC heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Manting ChoyDepartment of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Weihao LiangDepartment of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Jiangui HeDepartment of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Michael FuDepartment of Medicine, Sahlgrenska University Hospital/Östra Hospital, Gothenburg, Sweden.
Yugang DongDepartment of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Xin HeDepartment of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Chen LiuDepartment of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe aims of this study were to explore phenotypes of heart failure with preserved ejection fraction (HFpEF) and evaluate differential effects of spironolactone treatment. METHODS AND

resultsA swap-stepwise algorithm was used for variable selection. Latent class analysis based on 10 selected variables was employed in a derivative set of 1540 patients from the TOPCAT trial. Cox proportional hazard models were used to evaluate the prognoses and effects of spironolactone treatment. Three phenotypes of HFpEF were identified. Phenotype 1 was the youngest with low burden of co-morbidities. Phenotype 2 was the oldest with high prevalence of atrial fibrillation, pacemaker implantation, and hypothyroidism. Phenotype 3 was mostly obese and diabetic with high burden of other co-morbidities. Compared with phenotype 1, phenotypes 2 (hazard ratio [HR]: 1.46; 95% confidence interval [CI]: 1.14-1.89; P = 0.003) and 3 (HR: 2.35; 95% CI: 1.80-3.07; P < 0.001) were associated with higher risks of the primary composite outcome. Spironolactone treatment was associated with a reduced risk of the primary outcome only in phenotype 1 (HR: 0.63; 95% CI: 0.40-0.98; P = 0.042).

conclusionsThree distinct HFpEF phenotypes were identified. Spironolactone treatment could improve clinical outcome in a phenotype of relatively young patients with low burden of co-morbidities.

Indexed as

Heart FailureSpironolactoneHospitalizationHumansMineralocorticoid Receptor AntagonistsPhenotypeStroke VolumeMineralocorticoid Receptor AntagonistsSpironolactoneHeart failure with preserved ejection fractionLatent class analysisPhenotypeSpironolactoneVariable selection

Identifiers

PMID35587714
PMCPMC9288804

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.